NeoGenomics, Inc. (NASDAQ:NEO) Shares Acquired by Oak Family Advisors LLC

Oak Family Advisors LLC boosted its position in NeoGenomics, Inc. (NASDAQ:NEO) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 109,095 shares of the medical research company’s stock after purchasing an additional 1,454 shares during the quarter. Oak Family Advisors LLC’s holdings in NeoGenomics were worth $1,513,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Brown Advisory Inc. grew its holdings in NeoGenomics by 16.9% in the 4th quarter. Brown Advisory Inc. now owns 9,643,599 shares of the medical research company’s stock valued at $156,033,000 after buying an additional 1,397,397 shares in the last quarter. Bellevue Group AG purchased a new stake in NeoGenomics in the 1st quarter valued at $14,872,000. First Light Asset Management LLC grew its holdings in NeoGenomics by 29.6% in the 4th quarter. First Light Asset Management LLC now owns 3,926,756 shares of the medical research company’s stock valued at $63,535,000 after buying an additional 897,843 shares in the last quarter. Norges Bank purchased a new stake in NeoGenomics in the 4th quarter valued at $14,512,000. Finally, Kopp LeRoy C purchased a new stake in NeoGenomics in the 1st quarter valued at $14,062,000. 98.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Stephens reiterated an “overweight” rating and set a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. TD Cowen lowered their price target on NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Craig Hallum assumed coverage on NeoGenomics in a report on Wednesday, May 1st. They set a “buy” rating and a $26.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Benchmark reiterated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.89.

NeoGenomics Price Performance

Shares of NeoGenomics stock traded down $0.23 during trading on Thursday, reaching $16.20. The company’s stock had a trading volume of 350,319 shares, compared to its average volume of 840,403. The business has a 50 day moving average price of $14.87 and a 200-day moving average price of $14.80. The company has a market capitalization of $2.07 billion, a P/E ratio of -24.89 and a beta of 1.18. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The company has a quick ratio of 7.22, a current ratio of 2.01 and a debt-to-equity ratio of 0.37.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The firm had revenue of $164.50 million during the quarter, compared to analysts’ expectations of $161.82 million. During the same period in the previous year, the firm posted ($0.09) earnings per share. NeoGenomics’s revenue was up 12.0% on a year-over-year basis. As a group, sell-side analysts anticipate that NeoGenomics, Inc. will post -0.19 EPS for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.